This course has expired. View available courses.
Respirology
Setting the facts straight around triple therapy in COPD
Evidence-based treatment guidelines, including the Canadian Thoracic Society’s 2019 guideline, clearly define the place of triple inhaled therapy in the management of chronic obstructive pulmonary disease (COPD). However, clinicians may have inadequate knowledge about some aspects of COPD management, and may harbour misconceptions, including about the role of triple therapy versus dual inhaled therapy in […]
DURATION
1 hour
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
Mainpro+
EXPIRY DATE
2021-02-25
Evidence-based treatment guidelines, including the Canadian Thoracic Society’s 2019 guideline, clearly define the place of triple inhaled therapy in the management of chronic obstructive pulmonary disease (COPD). However, clinicians may have inadequate knowledge about some aspects of COPD management, and may harbour misconceptions, including about the role of triple therapy versus dual inhaled therapy in COPD, treatment selection for COPD according to the patient, differences between various COPD inhaler devices, and the safety profiles of inhaled corticosteroids (ICS) used in COPD. This educational program discusses these aspects of triple therapy in COPD and addresses prevailing myths/misconceptions.
The program is composed of four vignettes:
- Vignette 1: Disease burden and approach to management
- Vignette 2: Triple therapy for COPD: the evidence
- Vignette 3: Selecting the right inhaler for the patient
- Vignette 4: ICS Risks and benefits in COPD
The vignettes cover available data and current recommendations for COPD management, and also include interactive patient case studies, to provide clinicians with a comprehensive update on this topic.
Faculty
- Charles K.N. Chan MD, FRCPC, FCCP, FACP
- Gordon Dyck, MD, MCFP, BSc(Med), BA
- Suzanne Levitz, M.D.,C.M., CCFP
- Jonathan Peck, MD, CCFP
Learning objectives
On completion of this program, participants should be able to:
- Describe the place of triple inhaled therapy versus dual bronchodilators in the management of chronic obstructive pulmonary disease (COPD), and how treatable traits (symptoms vs exacerbations) should drive the choice of treatment
- Discuss the selection of inhaled drug therapy for COPD according to the patient
- Describe the differences in ease of use, minimum inspiratory flow requirements and peak inspiratory flow requirements for various COPD inhaler types
- Discuss the safety profile of inhaled corticosteroids in triple combination regimens for COPD